# Peter Finan

> Peter Finan is a Series A investor at Epidarex Capital backing Biotechnology and Genetics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Epidarex Capital](https://shizune.co/investors/profile/epidarex-capital)
- Location: Edinburgh, United Kingdom
- Total investments: 6
- Last investment: Sep 2024
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/peter-finan-048841b/

Peter Finan is a Series A investor at Epidarex Capital in Edinburgh focused on Biotechnology and Genetics. Pete Finan is the former head of the Novartis Institute of BioMedical Research (NIBR) site in the UK where he oversaw the activities of 350 scientists and clinicians working in the respiratory disease area. Prior to this he was an Executive Director in the Developmental and Molecular Pathways department at NIBR in Cambridge, Massachusetts leadingprograms in oncology, inflammation and regenerative medicine and Head of Biology at Karus Therapeutics. Pete is also a Partner at Epidarex Capital and has led / co-led the financing of six new companies in the Epidarex portfolio. He has a BSc and PhD from the University of Leeds.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 33% |
| Genetics | 1 | 17% |
| Biopharma | 1 | 17% |
| Recycling | 1 | 17% |
| Health Care | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Seed | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 33% |
| Canada | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M | Series B | Sep 09, 2024 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M | Series B | Mar 02, 2022 |  |
| Leucid Bio | Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts. | $15.9M | Series A | Oct 21, 2021 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $6.5M | Series A | Nov 30, 2018 |  |
| Epsilogen | IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $2.6M | Series A |  |  |
| Clean Metals Recycling | Clean Metals Recycling is a metal recycling company that uses cutting-edge environmental services to turn industrial waste into valuable metal byproducts. | $4.2M | Seed |  |  |

6 of 6 investments shown.

## Co-investors
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [ALSA Ventures](https://shizune.co/investors/profile/alsa-ventures) — VC Fund, 2 deals together
- [British Patient Capital](https://shizune.co/investors/profile/british-patient-capital) — VC Fund, 2 deals together
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 2 deals together
- [2invest](https://shizune.co/investors/profile/2invest) — VC Fund, 1 deal together
- [AlbionVC](https://shizune.co/investors/profile/albion-vc) — VC Fund, 1 deal together

## About Epidarex Capital

VC Fund · Bethesda, United States

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

5 contacts available at Epidarex Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Elizabeth Roper | Partner | https://shizune.co/investors/profile/elizabeth-roper |
| Peter Finan | Partner | https://shizune.co/investors/profile/peter-finan |
| Terri Burke | Venture Partner | https://shizune.co/investors/profile/terri-burke |
| Kyparissia Sirinakis | Founder & Managing Partner | https://shizune.co/investors/profile/kyparissia-sirinakis |
| Sinclair Dunlop | Managing Partner | https://shizune.co/investors/profile/sinclair-dunlop |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Peter Finan invest in?

Peter Finan invests primarily in Biotechnology, Genetics and Biopharma startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Peter Finan last invest?

The most recent investment recorded for Peter Finan closed in Sep 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co